Moderna, Inc. (MRNA)
Moderna Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?
Given the uncertainty around its top-line growth, short-term investors should exercise caution when investing in MRNA stock.
Moderna (MRNA) Advances But Underperforms Market: Key Facts
In the latest trading session, Moderna (MRNA) closed at $34.71, marking a +0.26% move from the previous day.
Down 93%, Is It Finally Time to Buy Moderna?
As we near the five-year anniversary of the COVID-19 pandemic, it's a good time to revisit the drugmaker stock that was top of mind back then. A few years ago, Moderna (MRNA 0.93%) stock soared on the back of the highly successful vaccine it developed in record time.
Moderna (MRNA) Presents at Barclays 27th Annual Global Healthcare Conference (Transcript)
Moderna (NASDAQ:MRNA ) Barclays 27th Annual Global Healthcare Conference March 11, 2025 1:30 PM ET Company Participants Rose Loughlin - EVP of Research Lavina Talukdar - SVP, Head of IR Conference Call Participants Gena Wang - Barclays Gena Wang Good afternoon, everyone. My name is Gena Wang.
Why Moderna Stock Has Surged 20% This Week Despite Mixed News
Moderna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open market. The post Why Moderna Stock Has Surged 20% This Week Despite Mixed News appeared first on Investor's Business Daily.
Moderna: Insider Buy Signal
Insider buying signals a market shift for Moderna, Inc. after years of relentless sales, with CEO Stephane Bancel purchasing MRNA shares due to perceived undervaluation. Moderna cut revenue guidance for 2025 to $1.5 to $2.5 billion, though the biotech has a strong pipeline of 10 drugs targeting a $30 billion market. Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities.
Here's Why Moderna Stock Soared 16% on Wednesday
The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.
Why Moderna Stock Zoomed Nearly 16% Higher on Wednesday
A big legal victory across the Atlantic Ocean was the news propelling Moderna (MRNA 15.94%) stock to a significant price surge on Hump Day. The win by the company, best known as the producer of the Spikevax COVID vaccine, pushed its stock nearly 16% higher during the trading session.
S&P 500 Gains and Losses Today: Moderna Stock Pops as Execs Buy Shares, Express Cancer Vaccine Optimism
Major U.S. equities indexes fluctuated on Wednesday before gaining momentum in the afternoon to close the session higher.
Moderna, Inc. (MRNA) TD Cowen 45th Annual Health Care Conference
Moderna, Inc. (NASDAQ:MRNA ) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET Corporate Participants Stephen Hoge - President Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren All right, well, good morning, everyone. Tyler Van Buren here, Senior Biotech Analyst at TD Cowen.
Moderna shares jump on insider stock purchases
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares moved higher after it was disclosed the company insiders have purchased $6 million in shares. According to filings with the Securities and Exchange Commission (SEC), CEO Stephane Bancel purchased 160,314 shares for $5 million.
Coatue's Philippe Laffont Just Bought Shares of This Beaten-Down Growth Stock That Wall Street Predicts Will Soar 80%
The S&P 500 has soared in recent times, delivering two consecutive years of double-digit gains, and investors -- from billionaires to small retail investors -- have piled into some of the biggest winners. I'm talking about technology stocks, and, more specifically, players operating in the high-growth area of artificial intelligence (AI).
